Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada OAKVILLE, ON / ACCESSWIRE / April 12, 2022 / NeonMind...
Announced today plans to launch 10 specialty mental health clinics over the next 3 years through alliances ...
Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge...
Announced today it is setting up to offer low dose intravenous ketamine therapy for mood and anxiety ...
Announced today it has released preclinical data demonstrating the efficacy of psilocybin in reducing ...
The world may be a step closer to successfully treating obesity with psilocybin. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology...
Announces today it has filed a new patent application with the United States Patent and Trademark Office ...
NeonMind Biosciences (CSE: NEON) (OTC: NMDBF) is another step closer to treating the global obesity epidemic. At the moment, worldwide obesity has tripled since 1975, says the World Health Organization....
Provided a summary of business highlights on the Company's activities and progress across its Pharmaceutical ...
NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) is a step closer to bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders. With obesity, for example,...